[DE] NEUE ALKIN-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL [EN] NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS [FR] NOUVEAUX COMPOSES D'ALCYNE A EFFET ANTAGONISTE VIS-A-VIS DE MCH ET MEDICAMENTS CONTENANT CES COMPOSES
摘要:
This invention relates to alkyne compounds of general formula I in which the groups and residues A, B, W, X, Y, Z, R1, and R2 have the meanings specified in claim 1. Furthermore, the invention relates to pharmaceutical compositions containing at least one alkyne compound according to the invention. Due to the MCH receptor antagonistic activity, the pharmaceutical compositions of the present invention are suitable for the treatment of metabolic disorders and/or eating disorders, especially obesity and diabetes.
[DE] NEUE ALKIN-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL [EN] NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS [FR] NOUVEAUX COMPOSES D'ALCYNE A EFFET ANTAGONISTE VIS-A-VIS DE MCH ET MEDICAMENTS CONTENANT CES COMPOSES
摘要:
This invention relates to alkyne compounds of general formula I in which the groups and residues A, B, W, X, Y, Z, R1, and R2 have the meanings specified in claim 1. Furthermore, the invention relates to pharmaceutical compositions containing at least one alkyne compound according to the invention. Due to the MCH receptor antagonistic activity, the pharmaceutical compositions of the present invention are suitable for the treatment of metabolic disorders and/or eating disorders, especially obesity and diabetes.
A series of unsaturated carbonyls, quinones, and pyridinium salts have been effectively reduced to the corresponding saturated carbonyls, dihydroxybenzenes, and hydropyridines in moderate to high yields with tetrahydroxydiboron/water as a mild, convenient, and metal-free reduction system. Deuterium-labeling experiments have revealed this protocol to be an exclusive transfer hydrogenation process from
[Cp*RhCl2]2, catalyzes efficiently the transferhydrogenation of various quaternary pyridinium salts under mild conditions, affording not only piperidines but also 1,2,3,6‐tetrahydropyridines in a highly chemoselective fashion, depending on the substitution pattern at the pyridinium ring. The reduction is conducted in azeotropic formic acid/triethylamine (HCOOH‐Et3N) mixture at 40 °C, with catalyst loadings
of various nitrogenheterocycles, including but not limited to quinolines, isoquinolines, indoles and pyridinium salts, in an aqueous solution of HCO2H/HCO2Na under mild conditions. The catalyst shows excellent functional‐group compatibility and high turnover number (up to 7500), with catalyst loadings as low as 0.01 mol % being feasible. Mechanistic investigation of the quinolinereduction suggests
在温和条件下,显示出环金属化的铱络合物在HCO 2 H / HCO 2 Na的水溶液中催化各种氮杂环的转移加氢反应,包括但不限于喹啉,异喹啉,吲哚和吡啶鎓盐。该催化剂表现出出色的官能团相容性和高周转率(最高7500),催化剂用量低至0.01 mol%是可行的。对喹啉还原反应的机理研究表明,转移氢化反应是通过1,2和1,4加成途径进行的,催化转化受氢化物转移步骤的限制。
[DE] NEUE ALKIN-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL<br/>[EN] NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES D'ALCYNE A EFFET ANTAGONISTE VIS-A-VIS DE MCH ET MEDICAMENTS CONTENANT CES COMPOSES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2005103002A3
公开(公告)日:2006-02-02
[DE] NEUE ALKIN-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL<br/>[EN] NOVEL ALKYNE COMPOUNDS EXHIBITING AN MCH ANTAGONISTIC EFFECT AND DRUGS CONTAINING SAID COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES ALKYNE A EFFET ANTAGONISTE DE MCH ET MEDICAMENTS CONTENANT LESDITS COMPOSES